65th ASH Annual Meeting & Exposition: 906. Outcomes Research – Myeloid Malignancies: Real-World Treatment Patterns and Outcomes

Symposia: Outcomes Research—Myeloid Malignancies Oral and Poster Abstracts
Oral

Research, Non-Biological therapies, Clinical Research, health outcomes research, Chemotherapy, patient-reported outcomes, Diseases, real-world evidence, Therapies, registries, Myeloid Malignancies, Study Population, Human

Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)

Moderators:

Erin H. Breese, MD, PhD, and Jesus D Gonzalez Lugo, MD,

Disclosures:

No relevant conflicts of interest to declare.

12:00 PM

547

Durable Outcomes with Manageable Safety Leading to Prolonged Survival with Tagraxofusp for Treatment-Naive Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Updated Results from a European Named Patient Program

Emanuele Angelucci¹, Eric Deconinck², David Manteigas³^*, Michael Zuurman⁴^* and Marco Herling⁵^*

¹Hematology and Cellular Therapy, IRCCS Ospedale Policlinico San Martino, Genova, ITA
²Besançon University Hospital, Besançon, France
³Axial Group, Boulogne-Billancourt, France
⁴Menarini-Stemline, Zug, Switzerland
⁵Department of Hematology, Celltherapy, Hemostaseology and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany

12:15 PM

548

Real-World Treatment Patterns Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents

Amer M. Zeidan, MBBS, MHS¹, Halley Costantino²^*, Kushal Modi²^*, Tehseen Salimi³^*, Terri Washington³^* and Robert S. Epstein⁴^*

¹Yale University and Yale Cancer Center, New Haven, CT
²Cerner Enviza, North Kansas City, MO
³Taiho Oncology, Inc., Princeton, NJ
⁴Epstein Health LLC, Woodcliff Lake, NJ

12:30 PM

549

Impact of Hypomethylating Agents on Cardiovascular Disease Risk Among Patients with Myelodysplastic Syndromes

Diego Adrianzen Herrera, MD¹, Andrew Sparks, MS²^*, Mansour Gergi, MD³, Katherine Giorgio, MPH⁴^*, Pamela Lutsey, PhD, MPH⁴^* and Neil Zakai¹

¹Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT
²Biomedical Statistics Research Core at the University of Vermont, Burlington, VT
³Larner College of Medicine at the University of Vermont, Burlington, VT
⁴University of Minnesota School of Public Health, Minneapolis, MN

12:45 PM

550

Intensive Chemotherapy (IC) Followed By Oral Azacitidine (AZA) Maintenance Versus Venetoclax (VEN) Plus AZA for Patients (pts) with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Record (EMR) Database in the United States

Alice Mims, MD¹, Zhuoer Xie, MD, MS², Alberto Vasconcelos³^*, Maria Strocchia³^*, Lona Gaugler³^*, Sara Vergara, MD³^*, Ying Qiu, PhD³^*, David Rotter⁴^*, Ravi Potluri, MBA⁴^*, Thomas Prebet³^* and Jan Sieluk³^*

¹Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
²H. Lee Moffitt Cancer Institute, Tampa, FL
³Bristol Myers Squibb, Princeton, NJ
⁴Putnam PHMR, New York, NY

1:00 PM

551

Comparative Effectiveness of Reinduction Approaches for Pediatric Relapsed Acute Myeloid Leukemia

Caitlin W. Elgarten, MD^1,2, Regina M. Myers, MD¹, Alix E. Seif, MD, MPH^1,3, Yimei Li, PhD⁴^*, Daniel J. Zheng, MD¹, Naomi J Winick, MD⁵^*, Elaine Morgan, MD⁶, Rajen Mody, MD, MS⁷^*, Arunkumar Modi, MBBS⁸, Tamara P. Miller, MD⁹, Kelly Maloney, MD¹⁰^*, Mallorie M. Heneghan, MD¹¹, M. Monica Gramatges, MD, PhD¹², Brian T. Fisher, DO, MPH, MSCE¹³^*, Kelly D. Getz, PhD¹⁴^* and Richard Aplenc, MD, PhD^1,15

¹Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
²Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
⁴Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
⁵Simmons Cancer Center and Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX
⁶Children's Memorial Hosp., Chicago, IL
⁷University of Michigan, Ann Arbor, MI
⁸University of Arkansas For Medical Sciences, Little Rock, AR
⁹Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA
¹⁰Department of Pediatrics, Children's Hospital Colorado, Aurora, CO
¹¹Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Utah, Salt Lake City, UT
¹²Pediatric Hematology-Oncology, Texas Children's Hospital, Houston, TX
¹³Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA
¹⁴Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
¹⁵Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

1:15 PM

552

Cardiovascular-Related Mortality Risk in Primary Myelofibrosis in Pre-Ruxolitinib and Ruxolitinib Eras

Nosakhare Paul Ilerhunmwuwa, MBBS, MSc¹, Aditya Keerthi Rayapureddy, MD²^*, Ifeanyi Nnamdi Uche, MBBS¹, Mustafa Wasifuddin, MD³^* and Jen-Chin Wang, MD⁴

¹Department of Medicine, Brookdale University Hospital and Medical Center, Brooklyn, NY
²Department of Medicine, Interfaith Medical Center, Brooklyn, NY
³Brookdale University Hospital and Medical Center, Brooklyn, NY
⁴Division of Hematology/Oncology, Brookdale University Hospital and Medical Center, Brooklyn, NY

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

906.O3.6 906. Outcomes Research – Myeloid Malignancies: Real-World Treatment Patterns and Outcomes